Myocardial regulatory proteins and heart failure

European Journal of Heart Failure

Volumn 8, Issue 4, 2006, Pages 333-342

  Adamcová, Michaela ^a   Štěrba, Martin ^a   Šimůnek, Tomáš ^b   Potáčová, Anna ^a   Popelová, Olga ^a   Geršl, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Calcium sensitizers; Cardiac marker; Cardiac troponin; Heart failure; Myocardial stunning; Regulatory proteins

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM ION; CALCIUM SENSITIZER; CAPTOPRIL; CARVEDILOL; DIGOXIN; DOBUTAMINE; FELODIPINE; INOTROPIC AGENT; ISOSORBIDE 5 NITRATE; ITRACONAZOLE; LEVOSIMENDAN; PIMOBENDAN; REGULATOR PROTEIN; TROPONIN I; TROPONIN T; WARFARIN;

BINDING AFFINITY; CALCIUM CELL LEVEL; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; GENE MUTATION; GENETIC DISORDER; GENETIC LINKAGE; HEART MUSCLE INJURY; HEART PERFORMANCE; HOSPITAL COST; HUMAN; HYPOTENSION; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASODILATATION;

CARDIAC OUTPUT, LOW; HUMANS; TROPONIN I; TROPONIN T;

EID: 33744784601     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.09.007     Document Type: Review

References (120)

1. Bleumink G.S., Knetsch A.M., Sturkenboom M.C.J.M., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure-The Rotterdam Study Source. Eur Heart J 25 18 (2004) 1614-1619
2. Opie L.H. Heart. Physiology, from cell to circulation (1998), Lippincott-Raven, Philadelphia
3. Ebashi S., Endo M., and Ohtsuki I. Control of muscle contraction. Q Rev Biophys 2 (1969) 351-384
4. Greaser M.L., Yamaguchi M., Brekke C., Potter J., and Gergely J. Troponin subunits and their interactions. Cold Spring Harbor Symp Quant Biol 37 (1972) 235-244
5. Perry S.V. Troponin I: inhibitor or facilitator. Mol Cell Biochem 190 (1999) 9-32
6. Solaro R.J. Troponin C-troponin I interactions and molecular signalling in cardiac myofilaments. Adv Exp Med Biol 382 (1995) 109-115
7. Solaro R.J., and Rarick H.M. Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res 83 (1998) 471-480
8. Katz A.M. Physiology of the heart (2001), Lippincott Williams and Wilkins, Philadelphia
9. Wilkinson J.M., and Grand R.J.A. Comparison of amino acid sequence of troponin I from different striated muscles. Nature 271 (1978) 31-35
10. Pearlstone J., Carpenter M., and Smillie L. Amino acid sequences of rabbit cardiac troponin T. J Biol Chem 261 (1986) 16795-16810
11. Pharmacek M.S., and Leiden J.M. Structure, function and regulation of troponin C. Circulation 84 (1991) 991-1003
12. Cullen M.E., Dellow K.A., and Barton P.J.R. Structure and regulation of human troponin genes. Mol Cell Biochem 263 (2004) 81-90
13. Campbell A.P., van Eyk J.E., Hodges R.S., and Sykes B.D. Interaction of troponin I and troponin C: use of the two-dimension transferred nuclear overhauser effect to determine the structure of a Gly-110 inhibitory troponin I peptide analog when bound to cardiac troponin C. Biochim Biophys Acta 1160 (1992) 35-54
14. Schiaffino S., Gorza L., and Ausoni S. Troponin isoform switching in the developing heart and its functional consequences. Trends Cardiovasc Med 3 (1993) 12-17
15. Farah C.S., and Reinach F.C. The troponin complex and regulating of muscle contraction. FASEB J 9 (1995) 755-767
16. Townsend P.J., Barton P.J.R., Yacoub M.H., and Farza H. Molecular cloning of human cardiac troponin T isoforms: expression in developing and failing heart. J Mol Cell Cardiol 27 (1995) 2223-2236
17. Malhotra A. Role of regulatory proteins (troponin-tropomyosin) in pathological states. Mol Cell Biochem 135 (1994) 43-50
18. Adamcová M., and Pelouch V. Isoforms of troponin in normal and diseased myocardium. Phys Res 48 (1999) 235-247
19. Solaro J.R., and Burkart E.M. Functional defects in troponin and the systems. Biology of heart failure. J Mol Cell Cardiol 34 (2002) 689-693
20. Perry S.V. Vertebrate tropomyosin: distribution, properties and function. J Mol Cell Motil 22 (2001) 5-49
21. Humphreys J.E., and Cummins P. Regulatory proteins of myocardium. J Mol Cell Cardiol 16 (1984) 643-657
22. Ruiz-Opazo N., Weinberger J., and Nadal-Ginard B. Comparison of α-tropomyosin sequences from smooth and striated muscles. Nature 315 (1985) 67-70
23. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 66 (1986) 710-771
24. Marston S.B., and Redwood C.S. Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins-physiological and pathological implications. Circ Res 93 12 (2003) 1170-1178
25. Gregorio C.C. Models of thin filament assembly in cardiac and skeletal muscle. Cell Struct Funct 22 1 (1997) 191-195
26. Gregorio C.C., Weber A., Bondad M., Pennise C.R., and Fowler V.M. Requirement of pointed-end capping by tropomodulin to maintain actin filament length in embryonic chick cardiac myocytes. Nature 377 6544 (1995) 83-86
27. Sussman M.A., Baque S., Uhm C.S., et al. Altered expression of tropomodulin in cardiomyocytes disrupts the sarcomeric structure of myofibrils. Circ Res 82 1 (1998) 94-105
28. Gao W.D., Atar D., Liu Y.G., Perez N.G., Murphy A.M., and Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 80 (1997) 393-399
29. Solaro R.J. Troponin I, stunning, hypertrophy, and failure of the heart. Circ Res 84 (1999) 122-124
30. Brundel B.J.J.M., Ausma J., van Gelder I.C., et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 54 2 (2002) 380-389
31. Sorimachi H., Ishiura S., and Suzuki K. Structure and physiological function of calpains. Biochem J 328 (1997) 721-732
32. Canty Jr. M.J., and Te-Chung Lee. Troponin I proteolysis and myocardial stunning: now you see it-now you don't. J Moll Cell Cardiol 34 (2002) 375-377
33. Maekawa A., Lee J.K., Nagaya T., et al. Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion. J Mol Cell Cardiol 35 10 (2003) 1277-1284
34. McDonough J.L., Arrell D.K., and van Eyk J.E. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res 84 (1999) 9-20
35. Toyota N., Shimada Y., and Bader D. Molecular cloning and expression of chicken cardiac troponin C. Circ Res 65 (1989) 241-246
36. Murphy A.M., Jones L.I., Sims H.F., and Strauss A.W. Molecular cloning of rat cardiac troponin I and analysis of troponin I isoforms expression in developing rat heart. Biochemistry 30 (1991) 707-712
37. Hunkeler N.M., Kullman J., and Murphy A.M. Troponin I isoform expression in human heart. Circ Res 69 (1991) 1409-1414
38. Anderson P.A.W., Moore G.E., and Nassar R.N. Development changes in the expression of rabbit left ventricular troponin T. Circ Res 63 (1988) 742-747
39. Sabry M.A., and Dhoot G.K. Identification of and changes in the expression of troponin T isoforms in developing avian and mammalian heart. J Mol Cell Cardiol 21 (1989) 85-91
40. Saba Z., Nassar R., Ungerleider R.M., Oakeley A.E., and Anderson P.A.W. Cardiac troponin T isoform expression correlates with pathological descriptors in patients who underwent corrective surgery for congenital heart disease. Circulation 94 3 (1996) 472-476
41. Mesnard-Rouiller L., Mercadier J.J., Butler-Browne G., et al. Troponin T mRNA and protein isoforms in the human left ventricle: pattern of expression in failing and control heart. J Mol Cell Cardiol 29 (1997) 3043-3055
42. Mesnard L., Logeart D., Taviaux S., Dioring S., Mercadier J.J., and Samson F. Human cardiac troponin T: cloning and expression of new isoforms in the normal and failing heart. Circ Res 76 4 (1995) 687-692
43. Anderson P.A.W., Malouf N.N., Oakeley A.E., Pagan E.D., and Allen P.D. Troponin T isoform expression in humans: a comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 69 5 (1991) 1226-1233
44. Anderson P.A.W., Greig A., Mark T.M., et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult and failing heart. Circ Res 76 4 (1995) 681-686
45. Tobacman L.S., and Lee R. Isolation and functional comparison of bovine cardiac troponin T isoforms. J Biol Chem 262 9 (1987) 4059-4064
46. Nassar R., Malouf N.N., Kelly M.B., Oakeley A.E., and Anderson P.A.W. Force-pCa relation and troponin T isoforms of rabbit myocardium. Circ Res 69 (1991) 1470-1475
47. 2+ binding associated with troponin T isoform switching in developing rabbit heart. Circ Res 66 (1990) 1204-1216
48. Adamcová M., Geršl V., Štěrba M., Klimtová I., and Šimůnek T. Changes of cardiac troponin T in daunorubicin-induced cardiomyopathy. J Muscle Res Cell M 24 4-6 (2003) 342
49. Gao L., Kennedy J.M., and Solaro R.J. Differential expression of TnI and TnT isoforms rabbit heart during the perinatal period and during cardiovascular stress. J Mol Cell Cardiol 27 (1995) 541-550
50. Chen Z., Higashiyama A., Yaku H., et al. Altered expression of troponin T isoforms in mild left ventricular hypertrophy in the rabbit. J Mol Cell Cardiol 29 (1997) 2345-2354
51. Kim S.H., Kim H.S., and Lee M.M. Re-expression of fetal troponin isoforms in the postinfarction failing heart of the rat. Circ J 66 10 (2002) 959-964
52. Solaro R.J., Powers F.M., Gao L., and Gwathmey J.K. Control of myofilament activation in heart failure. Circulation 87 Suppl. VII (1993) 38-43
53. 2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation. Cardiovasc Res 57 1 (2003) 37-47
54. 2+-sensitivity. J Mol Cell Cardiol 34 (2002) 469-482
55. Swiderek K., Jaquet K., Meyer H.F., Schachtele C., Hofmann F., and Heilmeyer G.H. Sites phoshorylated in bovine cardiac troponin T and I. Characterization by P-NMR spectroscopy and phosphorylation by protein kinases. Eur J Biochem 190 (1990) 575-582
56. 2+ dependent actomyosin MgATPase activity and troponin T binding to tropomyosin F actin complex. Biochem J 288 (1992) 123-129
57. 2+ affinity of cardiac troponin C. J Biol Chem 270 51 (1995) 30773-30780
58. McConnell B.K., Moravec C.H.S., Morano I., and Bond M. Troponin I phosphorylation in spontaneously hypertensive rat heart: effect of β-adrenergic stimulation. Am J Physiol 273 (1997) H1440-H1451
59. Malhotra A., Nakouzi A., Bowman J., and Buttrick P. Expression and regulation of mutant forms of cardiac TnI in reconstituted actomyosin system: role of kinase dependent phosphorylation. Moll Cell Biochem 170 (1997) 99-107
60. Bodor G.S., Oakeley A.E., Allen P.D., Crimmins D.L., Ladenson J.H., and Anderson P.A.W. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Circulation 96 5 (1997) 1495-1500
61. Dunn M.J. Studying heart disease using the proteomic approach. Drug Discov Today 5 (2000) 76-84
62. McDonough J.L., Labugger R., Pickett W., et al. Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 103 1 (2001) 58-64
63. Perez N.G., Hashimoto K., McCune S., Altschuld R.A., and Marban E. Origin of contractile dysfunction in heart failure-calcium cycling versus myofilaments. Circulation 99 8 (1999) 1077-1083
64. Ruf T., Schulte-Baukloh H., Ludemann J., et al. Alterations of cross-bridge kinetics in human atrial and ventricular myocardium. Cardiovasc Res 40 3 (1998) 580-590
65. Takeda N. Cardiomyopathy. Molecular and immunological aspects (review). Int J Mol Med 11 (2003) 13-16
66. Redwood-Moolman C.S., Smook J.C., and Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 44 1 (1999) 20-36
67. Clarkson E., Costa C.F., and Machesky L.M. Congenital myopathies: diseases of the actin cytoskeleton. J Pathol 204 4 (2004) 407-417
68. Moolman J.C., Corfield V.A., Posen B., et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 29 3 (1997) 549-555
69. Gomes A.V., Barnes J.A., Harada K., and Potter J.D. Role of troponin T in disease. Mol Cell Biochem 263 1 (2004) 115-129
70. Knollmann B.C., and Potter J.D. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 11 5 (2001) 206-212
71. 2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res 86 11 (2000) 1146-1152
72. Robinson P., Mirza M., Knott A., et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 277 43 (2002) 40710-40716
73. Michele D.E., and Metzger J.M. Physiological consequences of tropomyosin mutations associated with cardiac and skeletal myopathies. J Mol Med 78 10 (2000) 543-553
74. Van Eyk J.E., and Hodges R.S. The biological importance of each amino acid residue of the troponin I inhibitory sequence 104-115 in the interaction with troponin C and tropomyosin-actin. J Biol Chem 263 (1988) 1726-1732
75. Murphy R., Mogensen J., Shaw A., et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363 (2004) 371-372
76. Hinkle A., and Tobacman L.S. Folding and function of the troponin tail domain: effects of cardiomyopathic troponin T mutations. J Biol Chem 278 (2003) 506-513
77. Olson T.M., Kishimoto N.Y., Whitby F.G., and Michels V.V. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 33 (2001) 723-732
78. Li D., Czernuszewicz G.Z., Gonzalez O., et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 104 (2001) 2188-2193
79. Mogensen J., Murphy R.T., Shaw T., et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 44 10 (2004) 2033-2040
80. Murphy R., Mogensen J., Shaw A., et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363 (2004) 371-372
81. James J., Zhang Y., Osinska H., Sanbe A., Klevitsky R., and Hewett T.E. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 9 (2000) 805-811
82. Perry S.V. Troponin T: genetics, properties and function. J Muscle Res Cell Motil 19 (1998) 575-602
83. Towbin J.A., and Solaro R.J. Genetics of dilated cardiomyopathy-more genes that kill. J Am Coll Cardiol 44 10 (2004) 2041-2043
84. Mair J. Progress in myocardial damage detection: new biochemical markers for clinicians. Crit Rev Clin Lab Sci 34 1 (1997) 1-66
85. Keffer J.H. Myocardial markers of injury. Am J Clin Pathol 105 3 (1996) 305-320
86. Adamcová M., Geršl V., Hrdina R., et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 125 5 (1999) 268-274
87. Missov E., Calzolari C., Davy J.M., et al. Cardiac troponin I in patients with hematological malignancies. Coron Artery Dis 8 8-9 (1997) 537-541
88. Missov E., and Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 138 (1999) 95-99
89. Healey J.S., Davies R.F., Smith S.J., Davies R.A., and Ooi D.S. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiol 19 4 (2003) 383-386
90. Ricchiuti V., Zhang J.Y., and Apple F.S. Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling. Clin Chem 43 6 (1997) 990-995
91. van der Laarse A. Hypothesis: troponin degradation is one of the factors responsible for deterioration of left ventricular function in heart failure. Cardiovasc Res 56 1 (2002) 8-14
92. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Hear J 2000; 21:1502-13.
93. Jaffe A.S., Ravkilde J., Roberts, et al. It's time for a change to a troponin standard. Circulation 102 (2000) 1216-1220
94. Ganong W.F. Review of medical physiology (1991), Prentice Hall International, London
95. Allen D.G., and Kentish J.C. Calcium concentration in the myoplasm of skinned ferret ventricular muscle following changes in muscle length. J Physiol 407 (1988) 489-503
96. 2+ and segment length dependence of isometric force kinetics in intact ferret cardiac muscle. Circ Res 73 (1993) 603-611
97. 2+ sensitivity of tension at short sarcomere length. Circ Res 77 (1995) 199-205
98. 2+ sensitivity of myofibrillar ATPase activity in skinned fibers from pig ventricles. Pflugers Arch 415 (1990) 741-746
99. Greenberg B., Borghi C., and Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser levosimendan?. Eur J Heart Fail 5 1 (2003) 13-21
100. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77 (1995) 107-113
101. + activity and positive inotropic effect of sulmazole in guinea pig ventricular myocardium. Comparison with a cardioactive steroid. Circ Res 68 (1991) 597-604
102. NielsenKudsk J.E., and Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure?. J Cardiovasc Pharmacol 26 1 (1995) S77-S84
103. Sorsa T., Pollesello P., and Solaro R.J. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem 266 1-2 (2004) 87-107
104. Haikala H., and Linden I.B. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26 1 (1995) S10-S19
105. Haikala H., Nissinen E., Etemadzadeh E., Levijoki J., and Linden I.B. Troponin C mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25 (1995) 794-801
106. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction-a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 18 (2002) 1422-1432
107. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 6 (2000) 1903-1912
108. Janssen P.M.L., Datz N., Zeitz O., and Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404 1-2 (2000) 191-199
109. Braun J.P., Schneider M., Kastrup M., and Liu J.S. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardio Thorac 26 1 (2004) 228-230
110. Labriola C., Siro-Brigiani M., Carrata F., Santangelo E., and Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 42 4 (2004) 204-211
111. Lilleberg J., Nieminen M.S., Akkila J., et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19 4 (1998) 660-668
112. Kaheinen P., Pollesello P., Levijoki J., and Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37 4 (2001) 367-374
113. Sonntag S., Sundberg S., Lehtonen L.A., and Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43 12 (2004) 2177-2182
114. Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., and Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 85 1 (1997) 23-29
115. Kivikko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107 1 (2003) 81-86
116. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40 10 (2002) 465-471
117. Follath F., Cleland J.G.F., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 9328 (2002) 196-202
118. Innes C.A., and Wagstaff A.J. Levosimendan-a review of its use in the management of acute decompensated heart failure. Drugs 63 23 (2003) 2651-2671
119. Figgitt D.P., Gillies P.S., and Goa K.L. Levosimendan. Drugs 61 5 (2001) 613-627
120. Gomes U.C.S., and Cleland J.G.F. Heart failure update. Eur J Heart Fail 1 3 (1999) 301-302